CN119818670A - 治疗癌症的药物组合 - Google Patents

治疗癌症的药物组合 Download PDF

Info

Publication number
CN119818670A
CN119818670A CN202411827485.1A CN202411827485A CN119818670A CN 119818670 A CN119818670 A CN 119818670A CN 202411827485 A CN202411827485 A CN 202411827485A CN 119818670 A CN119818670 A CN 119818670A
Authority
CN
China
Prior art keywords
sfrp2
antagonist
cells
mab
hsfrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411827485.1A
Other languages
English (en)
Chinese (zh)
Inventor
N·德摩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Publication of CN119818670A publication Critical patent/CN119818670A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202411827485.1A 2018-09-27 2019-09-27 治疗癌症的药物组合 Pending CN119818670A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862737155P 2018-09-27 2018-09-27
US62/737,155 2018-09-27
PCT/US2019/053651 WO2020069439A1 (en) 2018-09-27 2019-09-27 Pharmaceutical combination for the treatment of cancer
CN201980076608.3A CN113454114B (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980076608.3A Division CN113454114B (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合

Publications (1)

Publication Number Publication Date
CN119818670A true CN119818670A (zh) 2025-04-15

Family

ID=69953118

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411827485.1A Pending CN119818670A (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合
CN201980076608.3A Active CN113454114B (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980076608.3A Active CN113454114B (zh) 2018-09-27 2019-09-27 治疗癌症的药物组合

Country Status (12)

Country Link
US (1) US20210395351A1 (https=)
EP (1) EP3856784A4 (https=)
JP (1) JP7451506B2 (https=)
KR (1) KR102947706B1 (https=)
CN (2) CN119818670A (https=)
AU (1) AU2019351267A1 (https=)
BR (1) BR112021005525A2 (https=)
CA (1) CA3114173A1 (https=)
IL (1) IL281782A (https=)
MX (1) MX2021003274A (https=)
SG (1) SG11202102865WA (https=)
WO (1) WO2020069439A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269376A (zh) * 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 用抗pd-l1抗体治疗癌症的方法
WO2025199292A1 (en) * 2024-03-21 2025-09-25 Musc Foundation For Research Development A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523551A (ja) * 2008-05-15 2011-08-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血管形成の調節の新規ターゲット
WO2011119524A1 (en) * 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
US9759725B2 (en) * 2012-08-02 2017-09-12 Fred Hutchinson Cancer Research Center Treatment-induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins
EA037548B1 (ru) * 2015-06-24 2021-04-12 Янссен Байотек, Инк. Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
JP2018518526A (ja) * 2015-06-25 2018-07-12 アドバンスド アクセレレーター アプリケーションズ ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
ES3034233T3 (en) * 2016-01-22 2025-08-14 MabQuest SA Non-blocking pd1 specific antibodies
EP3582811B1 (en) 2017-02-14 2024-07-10 Novartis AG Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Also Published As

Publication number Publication date
KR102947706B1 (ko) 2026-04-03
AU2019351267A1 (en) 2021-05-13
JP2022502434A (ja) 2022-01-11
WO2020069439A1 (en) 2020-04-02
BR112021005525A2 (pt) 2021-06-29
JP7451506B2 (ja) 2024-03-18
MX2021003274A (es) 2021-09-28
SG11202102865WA (en) 2021-04-29
CN113454114B (zh) 2024-12-27
EP3856784A1 (en) 2021-08-04
EP3856784A4 (en) 2022-10-19
KR20210065146A (ko) 2021-06-03
IL281782A (en) 2021-05-31
US20210395351A1 (en) 2021-12-23
CA3114173A1 (en) 2020-04-02
CN113454114A (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
KR101831123B1 (ko) 세포내 항원에 대해 지향된 단일 도메인 항체
AU2018351006B2 (en) Anti-CD47 agent-based ovarian cancer therapy
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
JP7681401B2 (ja) がん処置のためのａｘｌ特異的抗体
US10335494B2 (en) Combination of aurora kinase inhibitors and anti-CD30 antibodies
KR20150130318A (ko) 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 치료법
KR20210034613A (ko) 퀴놀린 유도체 및 항체의 약물 조합
KR20120083359A (ko) ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법
US20240174749A1 (en) Methods of treating cancer with antibodies against tim3
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
Oyama et al. Patched 1-interacting peptide represses fibrosis in pancreatic cancer to augment the effectiveness of immunotherapy
WO2017139468A1 (en) Combination of ifn-gamma with erbb inhibitor for the treatment of cancers
CN113454114B (zh) 治疗癌症的药物组合
TWI765862B (zh) 基於過敏反應素-１拮抗劑之癌免疫增強劑
EP3897613A1 (en) Use of il-1beta binding antibodies
RU2838216C2 (ru) Фармакологическая комбинация для лечения рака
CN121311246A (zh) 癌症治疗与预防的组合疗法
HK40122434A (zh) 治疗癌症的药物组合
KR102544135B1 (ko) c-Kit을 표적으로 하는 면역접합체
KR20250131777A (ko) 암의 치료 및 예방을 위한 조합물
HK40092156A (en) Anti-cd47 agent-based ovarian cancer therapy
HK40092156B (en) Anti-cd47 agent-based ovarian cancer therapy
HK40036030B (en) Anti-cd47 agent-based ovarian cancer therapy
Mom Exploring targeted therapies in oncology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40122434

Country of ref document: HK